ProSense® users speaking at the conference about
cryoablation included ISVIR President Dr. Suyash Kulkarni, as well as Dr. Shuvro
Roy-Choudhury
CAESAREA, Israel, Jan. 16,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer of the ProSense®
System, a minimally-invasive cryoablation technology that destroys
tumors by freezing as an alternative to surgical tumor removal,
today announced that it participated at the Indian Society of
Vascular and Interventional Radiology (ISVIR) 24th
Annual Conference in Jaipur, India
that took place from January
11th-14th, 2024.
IceCure, along with its in-country distributor, Novomed,
exhibited and conducted hands-on ProSense® demonstrations and
training. ProSense® has regulatory clearance in India for indications including general
surgery and oncology for tissues of the breast, lung, kidney,
liver, and bone and was used to perform the first breast
cryoablation procedure in India in
June 2023 at the Kovai Medical Center
and Hospital in Coimbatore.
In his presentation titled "Ablation for Bone and Soft Tissue
Masses: How I Do It", ISVIR President Dr. Suyash Kulkarni, described the benefits of using
a liquid nitrogen cryoablation system. Dr. Kulkarni gave several
specific examples of how his team performed cryoablation to
successfully treat bone and soft tissue masses.
"With the advancement of technology, commercially available
cryoablation systems today are transforming the way interventional
radiologists can quickly, safely, and very effectively treat a
broad range of indications early, before open surgery or before
other more aggressive therapeutic methods are required," Dr.
Kulkarni stated. "At this year's ISVIR conference, more
interventional radiologists evaluated the advantages of using
cryoablation in their practices and hospitals."
During his scientific presentation on esoteric ablations, Dr.
Shuvro Roy-Choudhury shared his experience in using ProSense®️. Dr.
Roy-Choudhury, ISVIR 2024 Gold Medal recipient, Country director of
Interventional Therapies at the Narayana Hrudayalaya Group of
Hospitals, a Senior Interventional Radiologist working across two
continents and a leader in imaging and interventional medical
devices, commented, "Globally, cryoablation is reaching a tipping
point in broad adoption across medical specialties and particularly
in interventional radiology. I find ProSense®️ to be a great
cryoablation system out there, with several unique advantages and
was privileged to share my experience with it at ISVIR this
year."
"We've been very active in the Indian market where ProSense®
offers a highly desirable efficacy, safety, and cost profile for
indications, including breast cancer. At this year's ISVIR,
supported by our hands-on demonstrations and the presentations of
several key opinion leaders, ProSense® received strong interest
from a growing number of doctors and medical institutions," stated
Tlalit Bussi Tel-Tzure, VP Business Development & Global
Marketing.
About ProSense®
The ProSense® Cyroablation System provides a minimally
invasive treatment option to destroy tumors by freezing them. The
system uniquely harnesses the power of liquid nitrogen to create
large lethal zones for maximum efficacy in tumor destruction in
benign and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by
accelerating recovery, reducing pain, surgical risks, and
complications. With its easy, transportable design and liquid
nitrogen utilization, ProSense® opens that door to fast and
convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses how
cryoablation systems are transforming the way interventional
radiologists can treat indications and the belief that cryoablation
is reaching a tipping point in broad adoption across medical
specialties. Historical results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of
future research or trials will suggest identical or even similar
conclusions. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements include, among
others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the SEC
on March 29, 2023, and other
documents filed with or furnished to the SEC which are available on
the SEC's website, www.sec.gov. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/icecure-medicals-prosense-featured-at-indian-society-of-vascular-and-interventional-radiology-conference-key-opinion-leaders-highlight-benefits-of-cryoablation-302035658.html
SOURCE IceCure Medical